Physician profile
Robert Scott Kaplinsky
NPI 1982643235
$8,820.10
in general payments reported to CMS, 2019-2025
58 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 77% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $913 · 2021: $722 · 2022: $1,513 · 2023: $1,192 · 2024: $1,422 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,350.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $932.06 | 2019-2025 | Erleada |
| Pfizer INC. | $817.69 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $792.73 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $734.25 | 2019-2025 | Xtandi, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $495.98 | 2019-2025 | |
| Olympus America INC. | $484.84 | 2020-2025 | Itind System, Soltive, Olympus |
| Blue Earth Diagnostics | $435.39 | 2019-2025 | Posluma |
| Endo Pharmaceuticals INC. | $338.77 | 2019-2024 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $305.93 | 2023-2025 | Gemtesa, Orgovyx |
| Merck Sharp & Dohme LLC | $299.77 | 2020-2025 | Lynparza, Keytruda, Welireg |
| Urogen Pharma, INC. | $284.03 | 2022-2025 | Jelmyto |
| Procept Biorobotics Corporation | $245.35 | 2022-2025 | Aquabeam System |
| Abbvie INC. | $230.39 | 2019-2024 | |
| Endo USA, INC. | $162.29 | 2024-2025 | Xiaflex |
| Allergan, INC. | $146.25 | 2019-2021 |
Show all 56 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kaplinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.